Boniva I.V. Once-Quarterly Safety Concerns Few, But Renal Tests Advised
Roche/GlaxoSmithKline's once-quarterly osteoporosis therapy Boniva injection does not present serious safety concerns compared with oral bisphosphonates, labeling for the I.V. formulation of the drug suggests